CopeJBushwitzJAnGAntiguaAPatelAZumbergM. Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. Ann Pharmacother. 2015;49:270-277.
2.
AgenoWRivaNNorisP; for the FONDAIR study group. Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost. 2012;10:2291-2297.
3.
GarciaDABaglinTPWeitzJISamamaM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, suppl):e24S-e43S.
4.
JohnsonPNBenefieldECBuiPYGausmanJNMarlarRAGessourounMR. Fondaparinux monitoring: need for a local fondaparinux-calibrated anti–factor Xa assay. J Pediatr Pharmacol Ther. 2013;18:318-319.
